Xeljanz® use for RA on the rise (but so is its discontinuation rate)

Nearly half of Xeljanz® users discontinue the costly RA drug after one year

February 9, 2017

Prime research shows nearly half of Xeljanz® users discontinue the costly rheumatoid arthritis (RA) drug after one year

The FDA approved Tofacitinib (Xeljanz®) for people with RA who have an inadequate response to methotrexate. The study found that one in 10 members were potentially not following guidelines to use tofacitininb as second line therapy. Additionally, 44 percent of members discontinued the drug by one year. RA is a chronic condition that needs ongoing treatment; this study show there is opportunity for improvement. Plan sponsors should develop care and utilization management programs that encourage adherence and cost-effective treatment strategies.

Tofacitinib (Xeljanz®) Utilization Patterns and Persistency Among 4.4 Million Continuously Enrolled Commercially Insured Members Over Four Years (Fall 2016)

Related research

Scientific presentations

August 21, 2021

Real-world CAR-T treatment costs can range from $700,000 to $1 million

CAR-T treatment costs more than the CAR-T product itself; Prime’s real-world study of…

Scientific presentations

August 1, 2021

Prime’s analytics uncovers the hidden ups and downs behind the flat drug trend for MS DMDs

Insights from integrated medical and pharmacy claims show a big upswing in one…

Scientific presentations

June 21, 2021

Break autoimmune (AI) into indication-specific info for actionable strategy

Prime uses integrated medical and pharmacy data and breaks down largest drug category…